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Abstract
We identified that the angiotensin receptor antagonist, candesartan, has profound neurovascular protective properties
when administered after ischemic stroke and was associated with a proangiogenic state at least partly explained by vascular
endothelial growth factor A (VEGFA). However, the spatial distribution of vascular endothelial growth factor (VEGF) isoforms
and their receptors remained unknown. Protein analysis identified a significant increase in vascular endothelial grow factor
B (VEGFB) in the cerebrospinal fluid (CSF) and the ischemic hemispheres (with increased VEGF receptor 1 activation) of
treated animals (p,0.05) which was co-occurring with an increase in protein kinase B (Akt) phosphorylation (p,0.05). An
increase in VEGFA protein in the contralesional hemisphere corresponded to a significant increase in vascular density at
seven days (p,0.01) after stroke onset. Vascular restoration by candesartan after stroke maybe related to differential
regional upregulation of VEGFB and VEGFA, promoting a ‘‘prosurvival state’’ in the ischemic hemisphere and angiogenesis
in the contralesional side, respectively. These vascular changes in both hemispheres after effective treatment are likely to
contribute to enhanced recovery after stroke.
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Introduction
Reperfusion therapy with either fibrinolysis or mechanical clot
removal is the current standard of care for acute treatment of
ischemic stroke [1]. However, the treatment is limited by a short
time window and a fear of reperfusioninjury, includinghemorrhage
development. Vascular protection (reducing hemorrhage and
edema formation) has emerged as a promising strategy to improve
outcome and hasten recovery from acute ischemic stroke. Many
potential targets have been proposed [2] and growth factors, in
particular VEGF, have been identified as both neuroprotective and
vascular protective [3]. However, VEGF has the undesirable effect
of increasing vascular permeability, leading to increased edema and
hemorrhage in some models [4]. In our previous work, we
demonstrated profound neurovascular protection with candesartan,
an angiotensin receptor antagonist, and this was associated with an
increase in VEGF expression (as detected by a nonspecific enzyme-
linked immune sorbent assay (ELISA)) in the ischemic hemisphere
but decreased vascular permeability. The CSF from candesartan
treated animals stimulated tube formation in brain endothelial cells
but this proangiogenic effect was only partly blocked by a VEGFA
blocking antibody [5]. We used a rat model to determine the role of
VEGF isoforms and their receptors in vascular protection after
experimental stroke.
Results
Quantitative PCR array
Of the total of 84 genes tested in the PCR array, 12 reached the
threshold for upregulation and 10 reached the threshold for
downregulation more than 1.5 fold by candesartan when
compared to the saline-treated animals(n=2). The largest increase
was in VEGFB (Figure 1). These data suggest that candesartan
enhances the expression of VEGFB mRNA in a PCR array.
Hemorrhage
Candesartan treatment significantly lowered hemoglobin excess
(bleeding) in the ischemic hemisphere by about 50% (P=0.013)
(Figure 2) compared with saline-treated animals.
Vascular Endothelial Growth Factor Expression in CSF
Since our earlier work suggested a proangiogenic effect in the
CSF [5], we compared the concentrations of VEGFA and VEGFB
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24 hours after stroke. Approximately 3 fold higher VEGFB
protein was evident (P=0.007) (Figure 3). These data suggest
that candesartan increases VEGFB protein in the CSF 24 hours
after experimental stroke. The difference in VEGFA was not
significant (Figure 3).
Vascular Endothelial Growth Factor Expression in the
Brain
We also compared VEGF expression in the brain tissue in the
sham animals and saline or candesartan-treated animals at
24 hours after stroke. For the VEGFB expression, there was a
significant interaction between treatment groups and brain
hemisphere (P=0.010). For the saline treated animals, the
ischemic hemisphere had lower VEGFB protein compared with
the nonischemic hemisphere (P=0.012) (Figure 4b). However,
there was no significant difference in VEGFB expression between
the two hemispheres in the sham animals (P=0.88) or cande-
sartan-treated animals (P=0.29). Treatment with candesartan
resulted in a significant preservation of VEGFB in the ischemic
hemisphere (P=0.010) (Figure 4b), such that it approached that of
the nonischemic side. For VEGFA, the interaction between
treatment groups and brain hemisphere (P=0.06) almost reached
statistical significance. The ischemic hemisphere had higher
expression compared with that of the nonischemic hemisphere
in the saline group (P=0.007) (Figure 5). There was no significant
difference between the two hemispheres for the sham (P=0.78) or
candesartan groups (P=0.63). Candesartan treatment showed a
statistical trend of increasing VEGFA protein expression in the
nonischemic hemisphere (Figure 5). These data suggest that
candesartan preserves VEGFB protein in the ischemic hemisphere
and increases VEGFA protein in the nonischemic hemisphere.
Vascular Endothelial Growth Factor Receptor Expression
in the Brain
VEGF isoforms interact with VEGFR1 and VEGFR2 differ-
ently. VEGFB exerts is prosurvival effects predominantly through
VEGFR1 and VEGFA induces angiogenesis primarily through
VEGFR2 [6]. The degree of phosphorylation of these receptors is
used to quantify their activation. VEGFR1 (flt-1) was significantly
higher in the stroke hemisphere when compared to the nonstroke
Figure 1. PCR array. PCR array was performed on the brain tissue homogenates from candesartan and saline treated animals (n=2). Brain tissue
samples were taken from both hemispheres as shown in Figure 4a. Regulated genes are presented as fold changes. Positive values mean upregulated
and negative values mean downregulated.12 genes were upregulated and 10 genes were downregulated more than 1.5 fold in candesartan-treated
animals, compared to saline-treated animals. VEGFB was particularly upregulated by candesartan.
doi:10.1371/journal.pone.0024551.g001
Figure 2. Hemorrhage. ELISA was performed on the brain tissue form
candesartan and saline treatment animals 24 hours after stroke onset.
Treatment with candesartan significantly decreased hemoglobin excess
(*P,0.05) in the ischemic brain, as compared with the saline-treated
animals. Arrows indicate hemorrhagic transformation of the ischemic
lesion in a representative animal.
doi:10.1371/journal.pone.0024551.g002
ARB and Differential VEGF Expression after Stroke
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24551side (P=0.0036) for all treatment groups (Figure 6a). Candesartan
resulted in a significant decrease in VEGFR1 in both hemispheres
(P=0.014 for treatment effect) (Figure 6a) compared to the sham
or saline groups (P=0.040 and P=0.005, respectively) (Figure 6a).
Candesartan treatment did not result in any changes in VEGFR2
(flk-1) expression in either hemisphere (Figure 7a).
Candesartan treated animals showed a visual increase in
phospho-flt-1 (activation of VEGFR1) expression in the stroke
hemisphere (Figure 6b) and increased phospho-flk-1(activation of
VEGFR 2) expression in the nonstroke hemisphere (Figure 7b),
but neither achieved statistical significance. However, it is likely
that the number of animals included were too few to give the study
enough statistical power to demonstrate any differences, if they
exist (Figure 6b,7b).
These data suggest that candesartan may up-regulate VEGFR1
activation in the ischemic hemisphere and VEGFR2 activation in
the nonischemic hemisphere. This corresponds well to the
increased activity of the prosurvival VEGFB in the area of the
ischemia and the more proangiogenic VEGFA on the contralat-
eral side.
Akt and p38 MAPK Pathway Assay
Candesartan treated animals had an increased activation of the
prosurvival protein kinase B (Akt) (P=0.034) (Figure 8a) and a
Figure 3. VEGF expression in CSF. Western blot was performed on the cerebrospinal fluid (CSF) from candesartan and saline treatment animals at
24 hours after stroke onset. Treatment with candesartan significantly increased VEGFB (Figure 3a, **P,0.01) protein expression in the CSF. However,
no significant difference was found for the VEGFA protein expression (Figure 3b).
doi:10.1371/journal.pone.0024551.g003
Figure 4. VEGFB expression in the brain. Western blot was performed on brain tissue from sham animals, candesartan and saline treated
animals at 24 hours after stroke onset. Brain tissue samples were taken as shown in Figure 4a.There was a significant interaction between treatment
groups. For the saline-treated animals, the ischemic hemisphere had lower VEGFB expression compared with the nonischemic hemisphere
(P=0.012).However, there was no significant difference between the two hemispheres for the sham animals (P=0.88) or candesartan-treated animals
(P=0.29). Candesartan treatment significantly preserved VEGFB protein expression in the ischemic hemisphere (Figure 4b,*P,0.05) as compared with
saline-treated animals.
doi:10.1371/journal.pone.0024551.g004
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(Figure 8b), as determined by their phosphorylation status, in both
hemispheres. These data suggest that the upregulation of both
VEGFA and VEGFB resulted in a prosurvival state.
Vascular Density
Candesartan treated animals had a significantly higher
percentage of vascular tissue (P=0.020) (Figure 9b) and number
of blood vessels (P=0.045) (Figure 9a) compared with saline
treated animals in the nonischemic hemisphere. We have already
published the data from the ischemic hemisphere [5]. These data
suggest that candesartan increases vascular density in both
hemispheres after stroke.
Discussion
Functional magnetic resonance imaging (FMRI) in human stroke
victims clearly demonstrates the involvement of both ipsilateral and
contralateral hemispheres in recovery after stroke [7].This study
reports, for the first time, that candesartan promotes the differential
expression of both VEGFA and VEGFB and their receptors in the
brain and may be responsible for the creation of a prosurvival state
in both hemispheres after stroke. Our initial finding of a
proangiogenic factor in the CSF, only partly blocked by a VEGFA
antibody [5], led us to studies aimed at determining the impact of
these findings on both hemispheres after stroke. With isoform-
specific protein analysis on brain homogenates and CSF, we were
able to confirm a predominant induction of VEGFB in the ischemic
hemisphere with a concurrent increase in VEGFA in the
nonischemic hemisphere. Phosphorylation of the relevant VEGF
receptors in both the ischemic and contralesional hemispheres
supports this finding. This combination may be linked to recovery
by enhancing function in both hemispheres. Our earlier report of
increased VEGF in the ischemic hemisphere of candesartan treated
animals [5], reflected the inability of the nonspecific ELISA assay to
differentiate between VEGFA and VEGFB and is a more common
way to report VEGF quantification in the stroke literature. The
results of the PCR array data reported here identified VEGFB as an
important contributor to this finding in the ischemic hemisphere.
We detected no hint of increased gene expression of VEGFA after
Figure 5. VEGFA expression in the brain. The ischemic hemisphere
had higher VEGFA expression compared with the nonischemic
hemisphere (Figure 5, *P,0.05) in the saline-treated animals. However,
there was no significant difference between the two hemispheres in the
sham animals (P=0.78) or candesartan-treated animals (P=0.63).
Moreover, the interaction between treatment groups and brain
hemisphere (P=0.06) almost reached statistical significance. Treatment
with candesartan showed a statistical trend of increasing VEGFA protein
expression in the nonischemic hemisphere (Figure 5, P=0.062).
doi:10.1371/journal.pone.0024551.g005
Figure 6. VEGFR-1 expression in the brain. Treatment with candesartan significantly decreased VEGFR1(flt-1) expression in both hemispheres
compared with saline-treated or sham animals (Figure 6a, *P,0.05). VEGFR1 activation, as determined by their phosphorylation status, was not
significantly different among sham animals, candesartan, and saline-treated animals (Figure 6b). Candesartan treatment appeared to visually increase
VEGFR1 activation in the stroke side, but this did not achieve significance (Figure 6b).
doi:10.1371/journal.pone.0024551.g006
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fact that we were focused on the changes in the ischemic
hemisphere.
Although an understudied cousin of VEGFA, VEGFB has
already been shown to be important in recovery after ischemic
stroke [8] and in other models of neuronal and vascular injury
[9].It has been shown to be antiapoptotic [10],[11]and is only
mildly angiogenic [11]. It has the protective effects of VEGFA [3]
without the increase in vascular permeability that can be
devastating in acute stroke [12],[13].
We are first to report a significant increase in protein kinase B
(Akt) activation with angiotensin antagonism after stroke, with a
reciprocal decrease in p38 MAP kinase. A reciprocal regulation of
cell survival kinase Akt and stress induced p38 MAP kinase has
been shown to be necessary for the creation of a prosurvival state.
Our findings are supported by others who have reported a
favorable effect of candesartan on Akt phosphorylation in vascular
smooth muscle cells [14]. The prosurvival state is regulated via
Akt-mediated phosphorylation and inhibition of apoptosis signal
regulating kinase1 (ASK1), an upstream activator of p38 MAP
Figure 7. VEGF-2 expression in the brain. Candesartan treatment did not result in any changes in VEGFR2 protein expression (Figure 7a) or
VEGFR-2(flk-1) activation (Figure 7b), as determined by the phosphorylation status, compared with saline-treated or sham animals in both
hemispheres (Figure 7b).
doi:10.1371/journal.pone.0024551.g007
Figure 8. Akt and P38 pathway assay. Candesartan treatment significantly increased protein kinase B (AKT) activation (Figure 8a, *P,0.05) and
inhibited P-38 kinase activation (Figure 8b, **P,0.01) in both hemispheres.
doi:10.1371/journal.pone.0024551.g008
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a ‘‘molecular switch’’, such that inhibition results in angiogenesis
but blocked hyperpermeability [16]. This may offer an additional
explanation why the increase in VEGF and a proangiogenic state
we reported after stroke and candesartan was accompanied by an
actual decrease in permeability [5].
Angiogenesis in the nonischemic brain after stroke, as reported
here in treated animals, may be a key component of functional
recovery. Whether this is caused by, or related to, the increase in
VEGFA and VEGFB is under investigation. It is possible that this
‘‘prosurvival state’’, demonstrated in the candesartan-treated
animals and appearing to be very similar to that caused by
ischemic postconditioning [17], is the mediator of the functional
recovery. The differential regional induction of the isoforms of
VEGF may be neuroprotective, neurorestorative, or only
important in vascular protection. This will have to be determined
through extensive genetic and pharmacologic studies both in vitro
and in vivo.
In our study, we only focused on the effects of VEGFA,VEGFB
and their corresponding receptors to stroke recovery. However,
there is a possibility that other VEGF isoforms and VEGF
receptors might contribute to the recovery [18],[19]. Long-term
studies can better address the relationship between VEGF
expression, vascular restoration and functional outcome after
stroke. These studies are ongoing where an experimental stroke
model with a smaller infarct size will be utilized to enhance the
ability of the animals to thrive for prolonged periods after injury.
In summary, our data indicate that VEGFB and VEGFA and
their receptors are up-regulated by candesartan in the brain after
ischemia and the changes are seen differentially in both hemi-
spheres. Inhibition of p38 MAP kinase allows the positive benefits
(vascular protection and angiogenesis) of the VEGF isoforms to
occur without accompanying hyperpermeability. Harnessing the
restorative properties of the vasculature in both hemispheres is a
promising therapeutic strategy for ischemic stroke patients.
Methods
The experimental protocol was approved by the institutional
Animal Care and UseCommittee of the CharlieNorwood Veterans
Affairs Medical Center (09-04-008). Sixty adult male Wistar rats
(Charles River Breeding Company, Wilmington, Mass), weighing
between 270 and 300 g, were divided into sham, saline and
candesartan treatment groups. Temporary (3-hour) middle cerebral
artery occlusion (MCAO) was achieved using the intraluminal
suture model [20] under isoflurane anesthesia. 19–21 mm silicon
coated suture (403756PK10, Doccol Corporation, Redlands, CA)
was introduced from the external carotid artery (ECA) lumen into
the internal carotid artery (ICA) to block the origin of the right
middle cerebral artery (MCA). The animals were kept under
anesthesia for only 15 minutes for the surgical procedure.
Temperature was maintained at 3760.5uC using a controlled
heating system. At reperfusion, a single dose of 1 mg/kg
candesartan(Astra-Zeneca) or salinecontrolwas given intravenously
through a tail vein at a volume of 1 mL/kg. The candesartan dose
was previously shown to be neurovascular protective [5]. After
middle cerebral artery occlusion (MCAO), animals were divided
into four sets. The first set of animals were sacrificed at 24 hours
after stroke and brain tissue sliced at 2 mm intervals (B–E), then
separatedintotwohemispheresandsnap frozenandstoredatminus
Figure 9. Vascular density. Immunohistochemical staining was performed on the brain tissue from candesartan and saline treated animals 7 days
after stroke onset. Treatment with candesartan significantly increased the number of blood vessels (*P,0.05) (Figure 9a) and the percentage of
vascular tissue (*P,0.05) (Figure 9b) compared with saline-treated animals in the nonischemic hemisphere.
doi:10.1371/journal.pone.0024551.g009
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(n=13). A second set of animals had CSF collected from the
cisterna magna (n=7) at 24 hours. The third set of animals had
brain tissue collected for quantification of hemoglobin (n=27) at
24 hours and the last set of animals had brain tissue collected for
immunohistochemical analyses (n=13) at 7 days after stroke.
Hemorrhage Determination
At 24 hours after the onset of MCAO, animals were
anesthetized with a cocktail of ketamine (45 mg/kg) and xylazine
(15 mg/kg) via intramuscular injection then perfused with saline,
sacrificed and their brains were removed. The brain tissue was
sliced into seven 2 mm-thick slices (A–G) in the coronal plane. The
ischemic and non-ischemic hemispheres of the slices for ELISA
were separated and processed, using the non-ischemic side as a
control. After homogenizing the slices in the core of the infarct (B–
E) and taking the supernatants, ELISA was performed to measure
the hemoglobin in the brain tissue [21].
Quantitative PCR array analysis
Frozen brain tissue samples (C slice) from both hemispheres
(Figure 4a) were homogenized in TRIzol reagent (Invitrogen Life
Technologies, Carlsbad, CA). Total RNA was isolated using the
TRIzol reagent (Invitrogen) followed by RNeasy Mini Kit
(QIAGEN) purification according to the manufacturer’s instruc-
tions. Total RNA was subjected to cDNA preparations using RT2
first strand kit. Gene assay was performed using the Rat Growth
Factors RT2 Profiler
TM PCR Array kit (SABiosciences). Of 84
genes related to growth factors, a threshold of 1.5 was used to
identify genes of interest.
Western blot analysis
Frozen brain tissue samples (D slice) from both hemispheres
(Figure 4a) were homogenized in lysis buffer (RIPA). Homogenates
(or CSF samples) were centrifuged, protein concentration deter-
mined, and 100 mg of protein per lane was subjected to SDS-PAGE
andtransferredto nitrocellulose membranes.Membranes were then
blocked at room temperature for 1 h in 5% bovine serum albumin
(BSA) and incubated with rabbit polyclonal anti-VEGFB
(ab58461,abcam, 1:250, Cambridge, MA), VEGFA (07-1376,
Millipore, 1:200, Billerica, MA), rabbit antiphospho-S473Akt
(9271; Cell Signaling,1:500, Danvers, MA), polyclonal rabbit
antipan Akt (9272; Cell Signaling,1:1000, Danvers, MA), phos-
pho-p38 MAPK Kinase (Thr180/Tyr182) antibody (9211;Cell
Signaling,1:500, Danvers, MA), or p38 MAPK antibody (9212;Cell
signaling,1:1000,Danvers,MA),rabbitpolyclonalVEGFreceptor1
(VEGFR1) antibody (ab2350;abcam,1: 100, Cambridge, MA), anti-
phospho-Flt (Tyr 1213) (07-758;Millipore; 1;750, Billerica, MA),
rabbit polyclonal VEGF receptor 2 (VEGFR2) antibody (ab39256;
abcam,1: 750, Cambridge, MA) and anti-phospho-VEGF receptor
2 (Tyr 1054+Tyr 1059) antibody (ab5473; abcam,1:1000, Cam-
bridge, MA). Each was diluted in 0.1% Tween 20/20 mM Tris-
buffered saline (TBS) or 5% BSA. Protein loading was controlled
with rabbit anti-b actin (A5060; Sigma,1:5000, St. Louis, MO).
Protein levels were analyzed densitometrically, using Image J
software and were normalized to loading controls.
Vascular Density Determination
Seven days after MCAO and treatment with either candesartan or
saline, rats were anesthetized with an 85% ketamine/15% xylazine
combination and transcardially perfused with normal saline followed
by 4% paraformaldehyde. Brains were quickly removed and fixed in
4%paraformaldehyde for3 hours and then sliced into 2-mmcoronal
sections. These sections were further fixed in 4% paraformaldehyde
for 24 hours and then transferred to 70% isopropyl alcohol. The
immunohistochemical analyses using a primary antibody for laminin
(rabbit polyclonal; Novus Biologics, Littleton, Co), a biotinylated
secondary antibody (Vector Labs #B1205), and fluorescence
detection, were performed on slide-mounted, paraffin-embedded
5 mm thick sections taken as previously described [5]. In the striatum,
both the number of individual blood vessels and the vascular density
of these vessels were determined with Image J (US National Institutes
of Health, Bethesda) image processing program. Three images per
area per animal were analyzed and vascular density and the number
of vascular profiles averaged.
Statistical analysis
All data are presented as mean 6 standard error (SEM). Data
were evaluated for normality and data transformation or
nonparametric analysis approach was considered if data were
not normal. A 3 X 2 mixed model repeated measures analysis of
variance (RMANOVA) was used to study the effect of treatment
(sham, saline, and candesartan) and brain hemisphere (ischemic vs.
nonischemic) and their interaction on VEGFA, VEGFB,
VEGFR1, and VEGFR2. A 2 X 2 RMANOVA was used to
analyze the effect of treatment (saline vs candesartan) and brain
hemisphere (ischemic vs nonischemic) on AKT and P38. A
Tukey’s adjustment for multiple comparisons was used when
interpreting significant interaction effects. We also investigated the
candesartan effect on hemorrhage in the brain, VEGF expression
in the CSF, and vascular density compared with saline control
using two-sample t-test. Statistical significance was determined at
p,0.05 for all analyses. All analyses were performed using SAS
9.2 (SAS Institute Inc., Cary, NC).
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